<DOC>
	<DOCNO>NCT01154049</DOCNO>
	<brief_summary>This phase I , open-label , single arm trial , aim assess safety vaccine prepare sm14 healthy subject . The product immunogenicity evaluate conduct serology ( anti-sm14 antibody ) test cellular response antigen method ELI-SPOT . Each participant remain study approximately 4 month . The total study duration 10 month , consider period 6 month inclusion . Will include study subject male female , 18 49 year , manifest participate research signing Informed Consent Form . Eligible population study subject present screen significant change renal , cardiac liver function , complete blood count , clot , present acute chronic illness , chronic use medication , HIV infection immunodeficiency . Pregnant breastfeed woman include . Volunteers receive three dos vaccine prepared sm14 , dose contain 50 mcg antigen , associate adjuvant GLA-SE dose 10 mcg , interval 30 day application . Twenty volunteer include study . This convenience sample , establish first test product human , initial safety assessment .</brief_summary>
	<brief_title>Study Evaluate Safety Vaccine Prepared sm14 Against Schistosomiasis</brief_title>
	<detailed_description />
	<mesh_term>Schistosomiasis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Aged 18 49 year . Available followup throughout study period ( approximately 120 day ) . Ability understand sign inform consent form ( IC ) . HIV serology negative Absence helminth infection general ( nematode , cestode trematode , among Schistosoma mansoni ) inclusion study . Patients chronic use use past 45 day medication , except trifle nasal saline vitamin . Be good health without significant medical history . Screening physical examination without clinical significant abnormality . Screening laboratory test without significant abnormality accord normal standard evaluation investigator . Additional criterion females childbearing potential : Negative pregnancy test screening ; consistent use contraceptive method ( male female condom , diaphragm , IUD oral contraceptive `` patch '' ) . Women pregnant breastfeeding . Use cytotoxic immunosuppressive drug last six month , except spray nasal corticosteroid allergic rhinitis topical corticosteroid uncomplicated dermatitis . Immunoglobulin use 60 day prior vaccination . Use type vaccine 30 day prior vaccination . Plan receive vaccine period participation study ( four month ) Use type investigational medication period 30 day prior vaccination Use allergy shot antigen within 14 day prior vaccination . Psychiatric illness hinders adherence protocol , psychosis , obsessivecompulsive neurosis , bipolar disorder treatment , diseases require treatment lithium , suicide thought last 5 year prior inclusion . Presence neurological disease , liver disease kidney disease ( diseases lead hospitalization prolong treatment ) . History sickle cell anemia . Asplenia ( spleen removal ) . History alcohol use/abuse ( CAGE criterion ) illicit drug . Blood pressure 140/90 mmHg screen hypertension require drug treatment . Coagulopathy diagnose doctor report capillary fragility ( eg , bruising , bleeding , etc . ) injection blood sampling . Active malignancy ( eg , type cancer ) treat may relapse study . History allergy vaccine contain adjuvant compose lipid ( GLA MPL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Schistosomiasis</keyword>
	<keyword>Vaccine</keyword>
	<keyword>sm14</keyword>
</DOC>